Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients

Radiother Oncol. 2006 Aug;80(2):151-6. doi: 10.1016/j.radonc.2006.07.033. Epub 2006 Aug 21.

Abstract

Purpose: FDG PET is frequently used for radiotherapy (RT) planning to determine the tumour extent. Similarly, FMISO is used to assess the hypoxic sub-volume. The relationship between the volumes determined on the basis of FDG and FMISO was investigated. Additionally, the quantitative correlation of the tracers on a voxel basis was studied.

Methods: Twelve head-and-neck cancer (HNC) patients underwent FDG and FMISO PET examinations prior to RT treatment. The tumour volumes assessed by the two tracers and also the voxel-based joint uptake values were investigated. The characteristic shapes and patterns of the determined scatter plots were analyzed. A number of different variables such as the maximum uptake values of FDG and FMISO, the FDG and FMISO positive volumes, the slope m of the regression line and the scatter width sigma of the scatter plots were tested for their ability to stratify the patient group with respect to treatment outcome.

Results: A diversity of characteristic FDG-FMISO distributions was observed in the patient group. However, no general correlation of enhanced glucose metabolism and FMISO uptake was observed. The maximum uptake of FMISO (p=0.045) showed borderline significance for stratifying the patient group. FDG positive tumour volume, hypoxic fraction, maximum FDG uptake and m were not significant. Sigma turned out to be the most significant variable (p=0.008) to predict treatment success probabilities.

Conclusion: FMISO and FDG PET data provide independent information about the examined tumour. A quantification of the correlated tracer uptake seems to be meaningful.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Cell Hypoxia / physiology
  • Female
  • Fluorine Radioisotopes*
  • Fluorodeoxyglucose F18 / pharmacokinetics*
  • Glucose / metabolism
  • Head and Neck Neoplasms / diagnostic imaging*
  • Head and Neck Neoplasms / metabolism
  • Head and Neck Neoplasms / radiotherapy*
  • Humans
  • Male
  • Middle Aged
  • Misonidazole / analogs & derivatives*
  • Misonidazole / pharmacokinetics
  • Nitroimidazoles / administration & dosage
  • Positron-Emission Tomography / methods
  • Radiopharmaceuticals / pharmacokinetics*
  • Treatment Outcome

Substances

  • Fluorine Radioisotopes
  • Nitroimidazoles
  • Radiopharmaceuticals
  • fluoromisonidazole
  • Fluorodeoxyglucose F18
  • pimonidazole
  • Misonidazole
  • Glucose